TY - JOUR T1 - Comparing biomarkers for COVID-19 disease with commonly associated preexisting conditions and complications JF - medRxiv DO - 10.1101/2020.10.02.20205609 SP - 2020.10.02.20205609 AU - Jesse Huang Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/05/2020.10.02.20205609.abstract N2 - Severe coronavirus disease 2019 (COVID-19) has been associated with certain preexisting health conditions and can cause respiratory failure along with other multi-organ injuries. However, the mechanism of these relationships is unclear, and prognostic biomarkers for the disease and its systemic complications are lacking. This study aims to examine the plasma protein profile of COVID-19 patients and evaluate overlapping protein modules with biomarkers of common comorbidities.Blood samples were collected from COVID-19 cases (n=307) and negative controls (n=78) among patients with acute respiratory distress. Proteins were measured by proximity extension assay utilizing next-generation sequencing technology. Its associations to COVID-19 disease characteristics were compared to that of preexisting conditions and established biomarkers for myocardial infarction (MI), stroke, hypertension, diabetes, smoking, and chronic kidney disease.Several proteins were differentially expressed in COVID-19, including multiple pro-inflammatory cytokines such as IFN-γ, CXCL10, and CCL7/MCP-3. Elevated IL-6 was associated with increased severity, while baseline IL1RL1/ST2 levels were associated with a worse prognosis. Network analysis identified several protein modules associated with COVID-19 disease characteristics overlapping with processes of preexisting hypertension and impaired kidney function. BNP and NTpro-BNP, markers for MI and stroke, increased with disease progression and were positively associated with severity. MMP12 was similarly elevated and has been previously linked to smoking and inflammation in emphysema, along with increased cardiovascular disease risk.In conclusion, this study provides an overview of the systemic effects of COVID-19 and candidate biomarkers for clinical assessment of disease progression and the risk of systemic complications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementStudy data was provide by Massachusetts General Hospitalm (MGH) in collaboration with Olink Proteomics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was approved and conducted at the Massachusetts General Hospital, and resulting data have already been made publicly available by request.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStudy data is available for request as of October 2, 2020. https://info.olink.com/mgh-covid-study-overview-page ACE2Angiotensin-converting enzyme 2ARDSAcute respiratory distress syndromeBMIBody mass indexCVDCardiovascular-related deathCKDChronic kidney diseaseCOVID-19Coronavirus disease 2019eGFREstimated glomerular filtration rateHFHeart failureIL-6Interleukin-6IL1RL1/ST2Interleukin 1 receptor-like 1LEPLeptinMERSMiddle Eastern respiratory syndromeMIMyocardial infarctionNGSNext-generation sequencingNPPB/BNPB-type natriuretic peptideNPXNormalized protein expressionNT-proBNPN-terminal pro–B-type natriuretic peptidePEAProximity extension assaySARSSevere acute respiratory syndromeSARS-CoV2Severe acute respiratory syndrome coronavirus 2WGCNAWeighted gene correlation network analysis ER -